Analyst firms · UBS · SNY
UBS SNY price target and rating history
Sanofi (SNY) · Health Care
UBS rates Sanofi (SNY) Neutral, as of its latest action on Jan 16, 2026. It has published 3 rating actions on SNY since August 2022, including 0 upgrades and 2 downgrades.
- Current rating
- Neutral
- Price target
- Not stated
- Median target, all firms
- Too few
- Actions on SNY
- 3
Every UBS rating on SNY
- Jan 16, 2026DowngradeUBS downgrades to Neutral from Buy
- Jan 16, 2024
- Aug 9, 2022DowngradeUBS downgrades to Neutral from Buy
How other firms rate SNY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Peer Perform | Oct 9, 2026 | |
| RBC Capital Markets | Sector Perform | Sep 9, 2026 | |
| Morgan Stanley | Equal-Weight | May 1, 2026 | |
| BNP Paribas Exane | Neutral | $50 | Apr 20, 2026 |
| BofA Securities | Neutral | Feb 12, 2026 | |
| Citigroup | Neutral | Jan 27, 2026 | |
| UBS | Neutral | Jan 16, 2026 | |
| Barclays | Equal Weight | Jan 6, 2026 | |
| Guggenheim | Neutral | Dec 9, 2025 |
Questions about UBS and SNY
- What is UBS's rating on SNY?
- UBS rates SNY Neutral, a neutral rating, as of Jan 16, 2026.
- When did UBS last change its view on SNY?
- On Jan 16, 2026, UBS downgrades to Neutral from Buy.
More SNY rating histories
All UBS ratingsSNY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.